Alexander Stessin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Stessin has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Samuel Ryu
9 shared publications- Samuel Ryu
Stony Brook University Hospital
3 shared publications Chao Chen
2 shared publicationsCollin Noldner
Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, USA
2 shared publicationsDaniel Lozeau
2 shared publicationsEdward Valentine
Department of Radiation Oncology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
2 shared publications
Latest Publications
- Open Access
- 18 August 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (11) , 101881
Magnetic Resonance Imaging Radiomic Analysis of Radiation-Induced Morphea of the Breast: A Proof-of-Concept Study
- 18 August 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (11) , 101881
Open AccessMagnetic Resonance Imaging Radiomic Analysis of Radiation-Induced Morphea of the Breast: A Proof-of-Concept Study
- 1 February 2024
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (1) , 29-35
Stereotactic body radiation therapy (SBRT) for the treatment of primary breast cancer in patients not undergoing surgery
- 1 February 2024
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (1) , 29-35
Stereotactic body radiation therapy (SBRT) for the treatment of primary breast cancer in patients not undergoing surgery
- Open Access
- 30 August 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (9) , 4031-4036
Estrogen Receptor-negative Ductal CarcinomaIn Situ(DCIS) of the Breast – an Institutional Review of Outcomes
Background/Aim: Estrogen receptor (ER)-negative [ER(−)] invasive breast cancers (IBCs) are known to be more aggressive than their ER(+) counterparts. This is less well defined for ductal carcinoma in situ (DCIS). This study investigated the outcomes following the treatment of ER(−) DCIS. Patients and Methods: A total of 103 ER(−) DCIS patients diagnosed between 2004-2018 were retrospectively analyzed. Median follow-up was 63.9 months. Statistical analysis included descriptive statistics, non-parametric tests, T-test, logistic regression. The outcomes were compared to a group of 102 ER(+) DCIS patients from our institution. Results: Any breast event (BE) occurred in 10 (9.7%) patients at a median of 3.2 (1.7-7.2) years. The incidence of ipsilateral breast events (IBEs) was 5.8% (6/103). All IBE cases were ER(−) DCIS. All (n=4) contralateral breast events (CBEs) were ER(+) including 3 IBCs. Cumulative incidence of any BEs at 1, 2, and 5 years was 0%, 1.1%, and 9.1%, respectively. Among patients with ER(−) DCIS who developed BE, breast conserving surgery (BCS) had been performed for the initial DCIS in 90% of cases. In those without any BE, the BCS rate (vs. mastectomy) was 58.1% (p=0.08). Adjuvant radiotherapy after BCS was used less often among patients with vs. without subsequent BE (55.5% vs. 77.4%) (p=0.22). Predictors for BE occurrence were not identified. The incidence of any BE among patients with ER(+) DCIS was 6.9% and was not significantly different compared to ER(−) DCIS group (p=0.46). Conclusion: ER(−) DCIS outcomes were similar to our institutional ER-positive DCIS group and the previously reported ones for predominantly ER-positive DCIS cohorts.
- 30 August 2023
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (9) , 4031-4036
Open AccessEstrogen Receptor-negative Ductal CarcinomaIn Situ(DCIS) of the Breast – an Institutional Review of Outcomes
Background/Aim: Estrogen receptor (ER)-negative [ER(−)] invasive breast cancers (IBCs) are known to be more aggressive than their ER(+) counterparts. This is less well defined for ductal carcinoma in situ (DCIS). This study investigated the outcomes following the treatment of ER(−) DCIS. Patients and Methods: A total of 103 ER(−) DCIS patients diagnosed between 2004-2018 were retrospectively analyzed. Median follow-up was 63.9 months. Statistical analysis included descriptive statistics, non-parametric tests, T-test, logistic regression. The outcomes were compared to a group of 102 ER(+) DCIS patients from our institution. Results: Any breast event (BE) occurred in 10 (9.7%) patients at a median of 3.2 (1.7-7.2) years. The incidence of ipsilateral breast events (IBEs) was 5.8% (6/103). All IBE cases were ER(−) DCIS. All (n=4) contralateral breast events (CBEs) were ER(+) including 3 IBCs. Cumulative incidence of any BEs at 1, 2, and 5 years was 0%, 1.1%, and 9.1%, respectively. Among patients with ER(−) DCIS who developed BE, breast conserving surgery (BCS) had been performed for the initial DCIS in 90% of cases. In those without any BE, the BCS rate (vs. mastectomy) was 58.1% (p=0.08). Adjuvant radiotherapy after BCS was used less often among patients with vs. without subsequent BE (55.5% vs. 77.4%) (p=0.22). Predictors for BE occurrence were not identified. The incidence of any BE among patients with ER(+) DCIS was 6.9% and was not significantly different compared to ER(−) DCIS group (p=0.46). Conclusion: ER(−) DCIS outcomes were similar to our institutional ER-positive DCIS group and the previously reported ones for predominantly ER-positive DCIS cohorts.
- Open Access
- 16 December 2022
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 39, 100566
Thyroid volume changes following adjuvant radiation therapy for breast cancer
- 16 December 2022
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 39, 100566
Open AccessThyroid volume changes following adjuvant radiation therapy for breast cancer
- Open Access
- 3 March 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Neuroinflammatory changes of the normal brain tissue in cured mice following combined radiation and anti-PD-1 blockade therapy for glioma
The efficacy of combining radiation therapy with immune checkpoint inhibitor blockade to treat brain tumors is currently the subject of multiple investigations and holds significant therapeutic promise. However, the long-term effects of this combination therapy on the normal brain tissue are unknown. Here, we examined mice that were intracranially implanted with murine glioma cell line and became long-term survivors after treatment with a combination of 10 Gy cranial irradiation (RT) and anti-PD-1 checkpoint blockade (aPD-1). Post-mortem analysis of the cerebral hemisphere contralateral to tumor implantation showed complete abolishment of hippocampal neurogenesis, but neural stem cells were well preserved in subventricular zone. In addition, we observed a drastic reduction in the number of mature oligodendrocytes in the subcortical white matter. Importantly, this observation was evident specifically in the combined (RT + aPD-1) treatment group but not in the single treatment arm of either RT alone or aPD-1 alone. Elimination of microglia with a small molecule inhibitor of colony stimulated factor-1 receptor (PLX5622) prevented the loss of mature oligodendrocytes. These results identify for the first time a unique pattern of normal tissue changes in the brain secondary to combination treatment with radiotherapy and immunotherapy. The results also suggest a role for microglia as key mediators of the adverse treatment effect.
- 3 March 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Open AccessNeuroinflammatory changes of the normal brain tissue in cured mice following combined radiation and anti-PD-1 blockade therapy for glioma
The efficacy of combining radiation therapy with immune checkpoint inhibitor blockade to treat brain tumors is currently the subject of multiple investigations and holds significant therapeutic promise. However, the long-term effects of this combination therapy on the normal brain tissue are unknown. Here, we examined mice that were intracranially implanted with murine glioma cell line and became long-term survivors after treatment with a combination of 10 Gy cranial irradiation (RT) and anti-PD-1 checkpoint blockade (aPD-1). Post-mortem analysis of the cerebral hemisphere contralateral to tumor implantation showed complete abolishment of hippocampal neurogenesis, but neural stem cells were well preserved in subventricular zone. In addition, we observed a drastic reduction in the number of mature oligodendrocytes in the subcortical white matter. Importantly, this observation was evident specifically in the combined (RT + aPD-1) treatment group but not in the single treatment arm of either RT alone or aPD-1 alone. Elimination of microglia with a small molecule inhibitor of colony stimulated factor-1 receptor (PLX5622) prevented the loss of mature oligodendrocytes. These results identify for the first time a unique pattern of normal tissue changes in the brain secondary to combination treatment with radiotherapy and immunotherapy. The results also suggest a role for microglia as key mediators of the adverse treatment effect.
- Open Access
- 1 January 2021
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 26 (1) , 143-148
Potential alternative treatment approach for pediatric patient with diffusely infiltrative primary rhabdomyosarcoma of the liver
Primary hepatic rhabdomyosarcoma is rare, making decisions regarding locoregional management with resection and/or conventional radiation difficult. We present a novel treatment approach for a pediatric patient diagnosed with rhabdomyosarcoma diffusely involving the liver. This patient underwent treatment with yttrium-90 (Y-90) microspheres followed by external beam radiation therapy (EBRT) to residual disease, interdigitated with systemic chemotherapy. Initial post-radiation imaging showed significant response to treatment, and she experienced minimal acute toxicities and no long-term toxicities. She developed recurrent PET-avid disease 23 months afterY-90 treatment, necessitating further local and continued systemic therapies. We report on the tumor control following Y-90 and EBRT treatment.
- 1 January 2021
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 26 (1) , 143-148
Open AccessPotential alternative treatment approach for pediatric patient with diffusely infiltrative primary rhabdomyosarcoma of the liver
Primary hepatic rhabdomyosarcoma is rare, making decisions regarding locoregional management with resection and/or conventional radiation difficult. We present a novel treatment approach for a pediatric patient diagnosed with rhabdomyosarcoma diffusely involving the liver. This patient underwent treatment with yttrium-90 (Y-90) microspheres followed by external beam radiation therapy (EBRT) to residual disease, interdigitated with systemic chemotherapy. Initial post-radiation imaging showed significant response to treatment, and she experienced minimal acute toxicities and no long-term toxicities. She developed recurrent PET-avid disease 23 months afterY-90 treatment, necessitating further local and continued systemic therapies. We report on the tumor control following Y-90 and EBRT treatment.
- 1 January 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 154, 87-92
NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer
- 1 January 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 154, 87-92
NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer
- 1 September 2017
- Published by Elsevier in Neuroscience Letters
- Vol. 658, 1-5
FTY720/fingolimod, an oral S1PR modulator, mitigates radiation induced cognitive deficits
- 1 September 2017
- Published by Elsevier in Neuroscience Letters
- Vol. 658, 1-5
FTY720/fingolimod, an oral S1PR modulator, mitigates radiation induced cognitive deficits